BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8675256)

  • 1. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides.
    Wielbo D; Simon A; Phillips MI; Toffolo S
    Hypertension; 1996 Jul; 28(1):147-51. PubMed ID: 8675256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense inhibition of hypertension in the spontaneously hypertensive rat.
    Wielbo D; Sernia C; Gyurko R; Phillips MI
    Hypertension; 1995 Mar; 25(3):314-9. PubMed ID: 7875755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen.
    Tomita N; Morishita R; Higaki J; Aoki M; Nakamura Y; Mikami H; Fukamizu A; Murakami K; Kaneda Y; Ogihara T
    Hypertension; 1995 Jul; 26(1):131-6. PubMed ID: 7541778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats.
    Makino N; Sugano M; Ohtsuka S; Sawada S
    Hypertension; 1998 May; 31(5):1166-70. PubMed ID: 9576130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.
    Peng JF; Kimura B; Fregly MJ; Phillips MI
    Hypertension; 1998 Jun; 31(6):1317-23. PubMed ID: 9622148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach.
    Tomita N; Morishita R; Higaki J; Tomita S; Aoki M; Kaneda Y; Ogihara T
    J Hypertens; 1995 Dec; 13(12 Pt 2):1767-74. PubMed ID: 8903649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligodeoxynucleotides directed against a novel angiotensinogen mRNA-stabilizing protein reduce blood pressure in spontaneously hypertensive rats.
    Klett CP; Anderson D; Sholook M; Granger JP
    Am J Physiol Regul Integr Comp Physiol; 2004 Sep; 287(3):R619-26. PubMed ID: 15155278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats.
    Sugano M; Tsuchida K; Sawada S; Makino N
    J Hypertens; 2000 Jun; 18(6):725-31. PubMed ID: 10872557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery.
    Wielbo D; Shi N; Sernia C
    Biochem Biophys Res Commun; 1997 Mar; 232(3):794-9. PubMed ID: 9126356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.
    Gyurko R; Wielbo D; Phillips MI
    Regul Pept; 1993 Dec; 49(2):167-74. PubMed ID: 8134617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats.
    Makino N; Sugano M; Ohtsuka S; Sawada S; Hata T
    Cardiovasc Res; 1999 Dec; 44(3):543-8. PubMed ID: 10690286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes.
    Phillips MI; Wielbo D; Gyurko R
    Kidney Int; 1994 Dec; 46(6):1554-6. PubMed ID: 7700004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense inhibition of angiotensinogen attenuates vasopressin release in the paraventricular hypothalamic nucleus of spontaneously hypertensive rats.
    Kagiyama S; Tsuchihashi T; Abe I; Matsumura K; Fujishima M
    Brain Res; 1999 May; 829(1-2):120-4. PubMed ID: 10350537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats.
    Gyurko R; Tran D; Phillips MI
    Am J Hypertens; 1997 May; 10(5 Pt 2):56S-62S. PubMed ID: 9160782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense inhibition of the brain kallikrein-kinin system.
    Madeddu P; Parpaglia PP; Glorioso N; Chao L; Chao J
    Hypertension; 1996 Dec; 28(6):980-7. PubMed ID: 8952586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension.
    Tang X; Mohuczy D; Zhang YC; Kimura B; Galli SM; Phillips MI
    Am J Physiol; 1999 Dec; 277(6):H2392-9. PubMed ID: 10600860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense.
    Kimura B; Mohuczy D; Tang X; Phillips MI
    Hypertension; 2001 Feb; 37(2 Pt 2):376-80. PubMed ID: 11230303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.
    Wu CH; Wang Y; Ma M; Mullick AE; Crooke RM; Graham MJ; Daugherty A; Lu HS
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30530571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats.
    Yuan LF; Sheng J; Lu P; Wang YQ; Jin T; Du Q
    Mol Med Rep; 2015 Sep; 12(3):4657-4663. PubMed ID: 26062941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.